Market Overview

UPDATE: JP Morgan Raises PT to $29 on Pfizer Following PD-991 Phase II Data

Share:
Related PFE
Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback
3 Highlights From A Spark Therapeutics Fireside Chat
Sabal Trust CO Buys United Parcel Service Inc, Bristol-Myers Squibb Company, Hanesbrands Inc, ... (GuruFocus)

JP Morgan reiterated Pfizer (NYSE: PFE) at Overweight and increased its price target from $28 to $29.

JP Morgan commented, "Following last week's phase II data for PD-991 in breast cancer and further feedback from physicians, we believe the product represents the most promising of Pfizer's next-generation pipeline assets, and we are incorporating it into our model. We see PD-991 as a multi-billion product opportunity, addressing a large segment of the breast cancer market (first-line advanced/metastatic HER2-/ER+) with few treatment options. More broadly, we believe PFE shares remain positioned to outperform as the company continues with its business unit divestiture process, returns significant capital to shareholders, and enters an attractive new product launch cycle."

Pfizer closed at $25.51 on Wednesday.

Latest Ratings for PFE

DateFirmActionFromTo
Oct 2017BMO CapitalMaintainsOutperform
Sep 2017Morgan StanleyUpgradesEqual-WeightOverweight
Aug 2017BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...